Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
Clinical trial NCT06276361 · COMPLETED
Trial details
- NCT number
- NCT06276361
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-26
- Primary completion
- 2025-07-07
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.